

35. The nucleic acid molecule as claimed in Claim 33, wherein the nucleotide sequence coding for the recombinase encodes CRE protein.

36. The nucleic acid molecule as claimed in any one of Claims 33, 34, or 35, wherein the recognition sequence comprises a LoxP recognition site.

37. The nucleic acid molecule as claimed in Claim 25, wherein the nucleotide sequence of interest encodes a polypeptide or RNA.

38. The nucleic acid molecule as claimed in Claim 37, wherein the RNA is antisense RNA or a ribozyme sequence.

39. The nucleic acid molecule as claimed in Claim 25, which is contained in a plasmid deposited under C.N.C.M. Assession No. I-1599.

40. A retroviral vector comprising a nucleic acid molecule according to any one of Claims 25-29.--

REMARKS

New claims 25-40 were originally prosecuted and cancelled without prejudice or disclaimer, in co-pending parent Application Serial No. 09/000,227.


If there is any fee due in connection with the filing of
this Preliminary Amendment, please charge the fee to our Deposit
Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 16, 2000

By:


Kenneth J. Meyers
Reg. No. 25,146

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000